GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Cash Flow for Lease Financing

LTR Pharma (ASX:LTP) Cash Flow for Lease Financing : A$ Mil (TTM As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Cash Flow for Lease Financing?

LTR Pharma's Cash Flow for Lease Financing for the six months ended in Jun. 2023 was A$0.00 Mil. LTR Pharma does not have enough years/quarters to calculate the Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2023.

Compared with last quarter (A$0.00 Mil in Jun. 2022 ), LTR Pharma's Cash Flow for Lease Financing remained the same in Jun. 2023 (A$0.00 Mil).


LTR Pharma Cash Flow for Lease Financing Historical Data

The historical data trend for LTR Pharma's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Cash Flow for Lease Financing Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Cash Flow for Lease Financing
- - -

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Cash Flow for Lease Financing - - -

LTR Pharma Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.



LTR Pharma Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


LTR Pharma (ASX:LTP) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines